QTTB Q32 Bio Inc.: Price-to-Projected Revenue Ratio
Q32 Bio Inc. develops advanced immune regulation methods to combat autoimmune pathologies. The expected P/S ratio provided by the GURU.Markets system reflects capital dynamics, where the current level is 4.90. Transparent resource management ensures the clarity of clinical stages, while a robust team of R&D specialists is retained through stock options, preventing the loss of valuable personnel.
q32bio.com (QTTB) - metric breakdowns and financial figures
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- debt and liquidity details:
- net income and valuation multiples indicators:
QTTB - Net Financial Result|Expected Profit Q32 Bio Inc.|QTTB - Price to Earnings Multiple|Forward P/E Multiple Q32 Bio|QTTB - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Q32 Bio Inc.|QTTB - Operating income before deduction of amortization|Earnings per share for the last twelve months Q32 Bio|QTTB - Net earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months q32bio.com|QTTB - Net earnings per one share growth for the current year|Expected earnings per share growth for next year Q32 Bio Inc.
- sales revenue and business income indicators:
Comprehensive company analysis:QTTB (Q32 Bio Corp)
Since Q32 Bio Inc. (QTTB) is in the clinical trial stage and has no commercial sales pending FDA approval, traditional revenue valuation remains speculative. The company's forward P/S trend reflects the ratio of current market capitalization to projected annual sales, allowing investors to promptly track market expectations for future revenues before they are actually confirmed in financial statements.
Competitor analysis
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|ABVX - Price-to-Projected Revenue Ratio|Projected Price to Revenue ADMA Corp (ADMA)|PTGX (Protagonist Therapeutics) - Forward Price-to-Revenue Multiple|IMVT (immunovant.com) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple KNSA|GRFS: Forward Price to Sales|Forward P/S Multiple ADPT|Price-to-Projected Revenue Ratio CLDX (Celldex Corp)|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|Market Cap to Expected Sales Ratio biocryst.com (BCRX)|VERA - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Dianthus Therapeutics Inc|PHVS (Pharvaris Corp) - Forward Price-to-Revenue Multiple|AbCellera Corp - Forward Price to Sales|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|precigen.com (PGEN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Pharming Group (PHAR)|Nektar Therapeutics Inc - Market Cap to Projected Revenue|Forward P/S Multiple UPB (Upstream Bio Corp)|ZBIO - Forward Price-to-Revenue Multiple|IMNM: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio gossamerbio.com GOSS|KalVista Pharmaceuticals, Inc. (KALV) - Price-to-Projected Revenue Ratio|Projected Price to Revenue Septerna, Inc. SEPN|Forward Price-to-Revenue Multiple PVLA|SVRA (Savara Pharma) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple RIGL (Rigel Pharmaceuticals)|Price to Expected Revenue Ratio ANAB|Forward P/S Multiple ATXS (Astria Therapeutics, Inc.)|enGene Holdings Inc - Price-to-Projected Revenue Ratio|RAPT - Price-to-Projected Revenue Ratio|Future Price to Revenue JBIO|ACRS: Forward P/S Multiple|kyvernatx.com - Forward Price to Sales|TLSA (Tiziana Life Sciences Ltd) - Forward P/S Multiple|Forward P/S Multiple Cabaletta Bio Inc.|Price-to-Projected Revenue Ratio Ventyx Bio (VTYX)|THTX (Theratechnologies, Inc) - Forward Price to Sales|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|ELDN - Forward Price-to-Revenue Multiple|Agenus Inc. - Forward P/S Multiple|CLYM - Forward P/S Multiple|ZURA (Zura Bio Limited) - Forward Price-to-Revenue Multiple|aTyr Pharmaceuticals - Forward Price to Sales|ADAG (Adagene Inc) - Forward P/S Multiple|Ikena Oncology, Inc. (IMA) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Shattuck Labs, Inc. (STTK)|Forward Price-to-Revenue Multiple equilliumbio.com EQ|Price-to-Projected Revenue Ratio Connect Biopharma Holdings Limited CNTB|IMUX - Forward Price-to-Revenue Multiple|ATRA: Forward Price-to-Revenue Multiple|IFRX - Forward P/S Multiple|X4 Pharmaceuticals, Inc. (XFOR) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ACET|CELU (Celularity Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio INmune Bio Corporation INMB|Price-to-Projected Revenue Ratio Barinthus Biotherapeutics (BRNS)|kezarlifesciences.com (KZR) - Projected Price to Revenue|SAB Biotherapeutics, Inc. - Forward Price-to-Revenue Multiple|Akari Therapeutics PLC - Price-to-Projected Revenue Ratio|ENLV: Forward Price-to-Revenue Multiple|Forward Price to Sales GOVX (GeoVax Corp)|EDSA: Forward P/S Multiple|IBIO (ibioinc.com) - Price-to-Projected Revenue Ratio|CARM (Carisma Therapeutics Inc) - Forward P/S Multiple|XTL Biopharmaceuticals Ltd (XTLB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|HCWB - Market Cap to Future Revenue Ratio|Aptevo Therapeutics Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales AIM|Aditxt Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio GRI Bio Inc GRI|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue HIND|REVB (Revelation Biosciences) - Forward P/S Multiple|Forward Price-to-Revenue Multiple indaptusrx.com (INDP)|Forward Price-to-Revenue Multiple SCNI (Scinai Immunotherapeutics Ltd.)|Market Cap to Expected Sales Ratio calcimedica.com|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|Projected Price to Revenue Allakos Inc|HOOK: Forward Price-to-Revenue Multiple|IGM Biosciences, Inc. - Price to Expected Revenue Ratio|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|OCEA: Price to Expected Revenue Ratio|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Price-to-Projected Revenue Ratio THRD
